Please use this identifier to cite or link to this item:
https://doi.org/10.1097/FTD.0000000000000298
Title: | Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers | Authors: | Lee, JW Pussegoda, K Rassekh, SR Monzon, JG Liu, G Hwang, S Bhavsar, AP Pritchard, S Ross, CJ Amstutz, U Carleton, BC Hayden, MR MacLeod, S Smith, A Brunham, L Aminkeng, F Shear, NH Koren, G Ito, S Madadi, P Rieder, MJ Kim, R Maher, M Flockhart, D |
Keywords: | Antineoplastic Agents Cisplatin Genetic Markers Hearing Loss Humans Pharmacogenetics Polymorphism, Genetic |
Issue Date: | 1-Aug-2016 | Publisher: | Ovid Technologies (Wolters Kluwer Health) | Citation: | Lee, JW, Pussegoda, K, Rassekh, SR, Monzon, JG, Liu, G, Hwang, S, Bhavsar, AP, Pritchard, S, Ross, CJ, Amstutz, U, Carleton, BC, Hayden, MR, MacLeod, S, Smith, A, Brunham, L, Aminkeng, F, Shear, NH, Koren, G, Ito, S, Madadi, P, Rieder, MJ, Kim, R, Maher, M, Flockhart, D (2016-08-01). Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. Therapeutic Drug Monitoring 38 (4) : 423-431. ScholarBank@NUS Repository. https://doi.org/10.1097/FTD.0000000000000298 | Abstract: | Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field, (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment, and management of cisplatin-induced hearing loss in children and adults, and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature, and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin-based chemotherapy. | Source Title: | Therapeutic Drug Monitoring | URI: | https://scholarbank.nus.edu.sg/handle/10635/235097 | ISSN: | 0163-4356 1536-3694 |
DOI: | 10.1097/FTD.0000000000000298 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
02_Cisplatin-Main Text.pdf | 236.21 kB | Adobe PDF | CLOSED | Published |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.